Edition:
United States

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

18.81USD
1:29pm EDT
Change (% chg)

$0.10 (+0.53%)
Prev Close
$18.71
Open
$18.87
Day's High
$19.14
Day's Low
$18.60
Volume
42,628
Avg. Vol
175,465
52-wk High
$34.98
52-wk Low
$17.10

Summary

Name Age Since Current Position

Hoyoung Huh

48 2012 Chairman of the Board

Sean McCarthy

51 President, Chief Executive Officer, Director

Debanjan Ray

40 2018 Chief Financial Officer and Head of Corporate Development

W. Michael Kavanaugh

61 2015 Chief Scientific Officer and Head - Research and Non-Clinical Development

Rachel Humphrey

56 2015 Chief Medical Officer

Charles Fuchs

57 2017 Director

Marion McCourt

58 2017 Director

John Scarlett

67 2016 Director

Frederick Gluck

82 Independent Director

Matthew Young

48 2015 Independent Director

Christopher Keenan

2018 Vice President, Investor Relations and Corporate Communications Vice President, Investor Relations and Corporate Communications

Biographies

Name Description

Hoyoung Huh

Dr. Hoyoung Huh M.D., Ph.D. serves as a Chairman of the Board of the company. He has served as a member of the board of directors since December 2011 and the chairman of our board of directors since February 2012. Dr. Huh has been a member of the board of directors of Geron Corporation since May 2010 and served as its chairman since September 2011. Dr. Huh also is a director of AntriaBio, Inc., a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. Dr. Huh served as a director of Addex Pharmaceuticals, a pharmaceutical discovery and development company, from May 2011 to May 2014. From February 2008 to December 2011, Dr. Huh was the chairman of the board of directors of BiPar Sciences, Inc. (“BiPar”), a biopharmaceutical company acquired in April 2009 by Sanofi-Aventis, a global pharmaceutical company. Dr. Huh served as BiPar’s president and chief executive officer from February 2008 to December 2009. Dr. Huh also served on the board of directors of Facet Biotech, a wholly-owned subsidiary of Abbott Laboratories, a global, broad-based health care company, from September 2009 to April 2010. Dr. Huh was a member of the board of directors of Nektar Therapeutics (“Nektar”), a clinical-stage biopharmaceutical company, from February 2008 to May 2009, and Nektar’s chief operating officer and senior vice president of Business Development and Marketing from March 2005 to February 2008. Prior to Nektar, Dr. Huh was a partner at McKinsey, a global management consulting firm, where he was in the biotechnology and biopharmaceutical sectors. Prior to McKinsey, he held positions as a physician and researcher at Cornell University Medical College and Sloan-Kettering Cancer Center. Dr. Huh holds an A.B. in biochemistry from Dartmouth College and an M.D. and Ph.D. in genetics and cell biology from Cornell University Medical College and Sloan-Kettering Institute.

Sean McCarthy

Dr. Sean A. McCarthy serves as a President, Chief Executive Officer, Director of the company. He has served as a member of the board of directors and our president and chief executive officer since August 2011. Previously, Dr. McCarthy has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto), Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium, Dr. McCarthy joined SGX Pharmaceuticals, where he spearheaded a wide range of large pharma partnerships as Vice President Business Development and helped drive a strategic reorientation of the company from a platform business model to product-focused oncology company, leading to a successful initial public offering in 2006. Immediately prior to joining CytomX, Dr. McCarthy was a transactional partner at Pappas Ventures from April 2006 to December 2010, where he was responsible for investments in therapeutic, medical device and molecular diagnostic companies. Dr. McCarthy is an author on multiple peer reviewed scientific publications, issued patents and filed patent applications. He received a B.Sc. in biochemistry and pharmacology at King’s College, University of London; an MBA from the Rady School of Management at the University of California San Diego; and a D.Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy currently serves as a member of the Board of Directors of the California Life Sciences Association.

Debanjan Ray

Mr. Debanjan Ray has been appointed as chief financial officer and head of corporate development since May 2017. Mr. Ray served as our senior vice president of corporate development & strategy from August 2015 to May 2017 and previously as our vice president of business development and alliance management from August 2011 to August 2015. Prior to joining CytomX, he served as vice president of business development at Itero Biopharmaceuticals, Inc. from May 2008 to August 2011. Mr. Ray was associate director, business development at Portola Pharmaceuticals from January 2006 to May 2008. Prior to that, Mr. Ray was an associate in the life sciences venture practice at J.P. Morgan Partners and a business analyst in the healthcare practice at McKinsey & Company. Mr. Ray holds an MBA from The Wharton School, University of Pennsylvania and received his B.S. degree in chemical engineering and biology from the Massachusetts Institute of Technology.

W. Michael Kavanaugh

Mr. W. Michael Kavanaugh, M.D. serves as a Chief Scientific Officer and Head - Research and Non-Clinical Development of the company. Since January 2015. Prior to joining us, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics, Inc. From February 2009 to December 2014, Dr. Kavanaugh held multiple positions in research and development at Five Prime Therapeutics, Inc. and led the growth of its therapeutic pipeline. Prior to that, Dr. Kavanaugh served as vice president of Novartis Vaccines & Diagnostics, Inc. and executive director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis as part of its acquisition of the Chiron Corporation in 2006, where he held positions as vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his M.D. from Vanderbilt University and his B.S. in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at University of California, San Francisco, and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of Medicine at University of California, San Francisco.

Rachel Humphrey

Dr. Rachel W. Humphrey, M.D. serves as a Chief Medical Officer of the company. since August 2015, having previously served as a member of our board of directors from May 2015 to August 2015Dr. Humphrey was vice president, head of immuno-oncology at Eli Lilly and Company, a global pharmaceutical company, from May 2015 to August 2015. From November 2013 to December 2014, Dr. Humphrey was vice president, head of immuno-oncology at AstraZeneca, a global pharmaceutical company. From January 2012 to October 2013, she was executive vice president and chief medical officer of Mirati Therapeutics, Inc., where she helped advance multiple assets through early stage clinical investigation. Prior to that, she served as vice president of product development at Bristol-Myers Squibb Company from May 2003 to January 2012. Prior to that, Dr. Humphrey held multiple positions in development at Bayer. Dr. Humphrey began her career as an oncology fellow and staff physician at the National Cancer Institute. Dr. Humphrey received her M.D. from Case Western Reserve University and received her B.A. from Harvard University.

Charles Fuchs

Dr. Charles S. Fuchs, M.D., MPH serves as Director of the Company. Fuchs has served as a member of our board of directors since October 2017. Dr. Fuchs has been the Richard Sackler and Jonathan Sackler Professor of Medicine, Director of the Yale Cancer Center and Physician-in-Chief of the Smilow Cancer Hospital since January 2017. He was previously professor of medicine at Harvard Medical School and chief of the gastrointestinal oncology division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute from July 2007 to December 2016. Dr. Fuchs received his medical degree from Harvard Medical School in 1986. He completed his medical residency at Brigham and Women’s Hospital, where he also served as chief medical resident, and completed his medical oncology fellowship at Dana-Farber Cancer Institute. In 1994, he received his M.P.H. from Harvard School of Public Health. We believe that Dr. Fuchs is qualified to serve on our board of directors due to his deep medical experience and service on the boards of directors of several cancer centers.

Marion McCourt

Ms. Marion McCourt serves as a Director of the Company. Ms. McCourt has served as a member of our board of directors since March 2017. Ms. McCourt has served as Senior Vice President, Commercial of Regeneron Pharmaceuticals, Inc. since February 2018. Prior to joining Regeneron, she served as President and Chief Operating Officer of Axovant Sciences, Inc. from April 2017 to February 2018. Previously, she served as Chief Operating Officer at Medivation from February 2016 until the company’s acquisition by Pfizer in September 2016. Prior to joining Medivation, Ms. McCourt served at Amgen Inc., first as Vice President and General Manager of Amgen’s Bone Health & Primary Care Business Unit from May 2013 to February 2014 and then as Vice President of U.S. Commercial Operations from February 2014 to January 2016. Before joining Amgen, Ms. McCourt held numerous positions over a twelve-year career at AstraZeneca starting in November 1999, a pharmaceutical and biopharmaceutical company, including most recently serving as Chief Operating Officer of AstraZeneca U.S. from December 2011 to March 2013. Ms. McCourt has served on the board of directors of Scynexis, a publicly-traded pharmaceutical company, since January 2017. Ms. McCourt holds a B.S. degree in Biology from Lafayette College. We believe that Ms. McCourt is qualified to serve on our board of directors due to her operational and commercial leadership experience at several public life sciences companies. Ms. McCourt’s service as a member of the Board will cease at the Annual Meeting scheduled to be held on June 13, 2018.

John Scarlett

Dr. John A. Scarlett, M.D. serves as Director of the Company. Dr. Scarlett has served as a member of our board of directors since June 2016. Dr. Scarlett currently serves as chief executive officer, president and a member of the board of directors of Geron Corporation, a public company. Since February 2015, Dr. Scarlett has also served as a member of the board of directors of Chiasma, Inc., a public company. Prior to joining Geron in September 2011, Dr. Scarlett served as president, chief executive officer and a member of the board of directors of Proteolix, Inc., from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., in November 2009. From February 2002 until its acquisition by Ipsen, S.A., in October 2008, Dr. Scarlett served as founder, chief executive officer and a member of the board of directors of Tercica, Inc., and also as its president from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as president and chief executive officer of Sensus Drug Development Corporation. In 1995, he cofounded Covance Biotechnology Services, Inc., and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as senior vice president of medical and scientific affairs at Novo Nordisk Pharmaceuticals, Inc. Dr. Scarlett holds a B.A. in chemistry from Earlham College and an M.D. from the University of Chicago, Pritzker School of Medicine. We believe Dr. Scarlett is qualified to serve on our board of directors based on his significant industry experience, medical background and extensive management experience in the life sciences sector.

Frederick Gluck

Mr. Frederick Gluck serves as an Independent Director of the company. Mr. Gluck has served as a member of our board of directors since September 2010 and was a member of the board of directors of CytomX Therapeutics, LLC until September 2010. Mr. Gluck previously served as a member of the board of directors of Amgen, Inc. from February 1998 to October 2011. He has also served as founding chairman of the board and CEO of our predecessor company, CytomX, LLC, from 2006 to 2008. Mr. Gluck currently serves as chairman of the board of Cynvenio Biosystems, Inc., a private company that was spun off from CytomX in 2008, where he has served on the board since 2008. He also currently serves as co-chairman of the board of TrueVision Systems Inc., a private company where he has served on the board since 2007. Mr. Gluck served as a consultant to McKinsey & Company, Inc., an international management-consulting firm (“McKinsey”), from July 1998 to July 2003. Prior to that, he was Vice Chairman and Director of Bechtel Group, Inc., an engineering, construction and project management company, from 1995 to July 1998. Mr. Gluck is a former partner of McKinsey, where he served from 1967 to 1995. Between 1988 and 1994, he was the Managing Director of McKinsey. He also serves as a director of the Foundation Board of the University of California, Santa Barbara, the Kavli Institute of Theoretical Physics and The New York Presbyterian Hospital (Emeritus). Mr. Gluck was the presiding director of the Hospital Corporation of America. Mr. Gluck received his B.S. from Manhattan College and M.S. from New York University in electrical engineering. We believe that Mr. Gluck is qualified to serve on our board of directors due to his extensive management experience, substantial experience in the life sciences industry and his well-known expertise in corporate strategy.

Matthew Young

Mr. Matthew P. Young serves as an Independent Director of the company. since September 2015. Mr. Young has served as a member of our board of directors since September 2015. Mr. Young has been Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc since February 2015 and previously served as its Senior Vice President and Chief Financial Officer since March 2014 and as its Senior Vice President, Corporate Development since April 2013. Prior to joining Jazz Pharmaceuticals, Mr. Young worked in investment banking for approximately 20 years. From February 2009 to April 2013, Mr. Young served as a managing director in global healthcare of Barclays Capital Inc., an investment banking firm, where his role included acting as the co-head of life sciences at Barclays Capital. From 2007 to 2008, Mr. Young served as a managing director of Citigroup Global Markets Inc., an investment banking firm, and from 2003 to 2007, as a managing director of Lehman Brothers Inc., an investment banking firm. From 1992 to 2003, Mr. Young served in various capacities at other investment banking firms. In 2015, he joined the board of directors of PRA Health Sciences, Inc., a public contract research company. Mr. Young received a B.S. in Economics and a M.B.A. from the Wharton School of the University of Pennsylvania..

Christopher Keenan

Basic Compensation

Name Fiscal Year Total

Hoyoung Huh

187,348

Sean McCarthy

3,213,340

Debanjan Ray

1,563,120

W. Michael Kavanaugh

1,382,260

Rachel Humphrey

1,539,700

Charles Fuchs

329,543

Marion McCourt

438,576

John Scarlett

166,621

Frederick Gluck

162,348

Matthew Young

168,598

Christopher Keenan

--
As Of  30 Dec 2017